Recent Breakthroughs in the Treatment of Alzheimer Disease
August 23rd 2021This NeurologyLive® Peers & Perspectives series features experts in the diagnosis and treatment of Alzheimer disease discussing the recent approval of aducanumab, its implications for Alzheimer disease, and other promising therapies and diagnostic technologies in development.
Preventing Secondary Stroke: Practical Application of Updated Guidelines
August 21st 2021Experts provide a summary of the management of commonly encountered risk factors for secondary ischemic stroke and transient ischemic attack based on the newly published 2021 AHA/ASA recommendations.
BTK Inhibitor Fenebrutinib Aims to Tackle Progressive MS in FENtrepid Trial
August 20th 2021The agent’s safety profile has been studied in more than 1200 individuals to date across several inflammatory diseases, with data indicating that the high selectivity of fenebrutinib may limit off-target effects.
It Is Time to Redefine Outcomes in Pediatric Epilepsy Surgery
August 16th 2021Successful epilepsy surgery in adults has been followed by forced normalization, depression, and memory issues, resulting in questions about the use of the metrics in the study of broader outcomes—a problem even more prominent in pediatric epilepsy surgery.
FDA Commissioner Calls for Independent Review of Agency Interactions on Aducanumab
July 9th 2021Janet Woodcock, MD, acting commissioner of the FDA, called for an inquiry by the Office of the Inspector General into possible interactions between agency officials and Biogen that "may have occurred outside of the formal correspondence process."
MRI in Multiple Sclerosis Guidelines Update: North America, Europe Align on New Recommendations
June 15th 2021These consensus guidelines are significant not only for their key updates to clinical practice but for their representation of a more unified, global approach to diagnosing and monitoring patients with multiple sclerosis.